Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
16.92
+0.24 (1.44%)
Oct 9, 2025, 4:00 PM EDT - Market closed
Zymeworks Revenue
Zymeworks had revenue of $48.73M in the quarter ending June 30, 2025, with 153.21% growth. This brings the company's revenue in the last twelve months to $122.87M, up 95.94% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$122.87M
Revenue Growth
+95.94%
P/S Ratio
10.37
Revenue / Employee
$429,605
Employees
286
Market Cap
1.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ZYME News
- 21 hours ago - InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors - Newsfile Corp
- 1 day ago - Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer - GlobeNewsWire
- 5 weeks ago - Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On - Seeking Alpha
- 5 weeks ago - Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit - Benzinga
- 5 weeks ago - Zymeworks halts development of cancer drug after trial setback - Reuters
- 5 weeks ago - Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager - GlobeNewsWire
- 7 weeks ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - GlobeNewsWire